Supplementary Figure 1: Representative photomicrographs of the spindle cell (A), round cell (B), and epithelioid (C) variants of undifferentiated sarcoma

Supplementary Figure 2: GISTIC analysis of recurrent focal copy number alterations

References:

1. Fletcher CDM, Chibon F, Mertens F. Undifferentiated/unclassified sarcomas. In: Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F, eds. WHO Classification of Tumours of Soft Tissue and Bone. 4th edition: IARC: Lyon; 2013:236-238. 2. Sugita S, Arai Y, Tonooka A, et al. A novel CIC-FOXO4 gene fusion in undifferentiated small round cell sarcoma: a genetically distinct variant of Ewing-like sarcoma. Am J Surg Pathol. 2014;38(11):1571-1576. 3. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001;19(12):3091-3102. 4. Pawel BR, Hamoudi AB, Asmar L, et al. Undifferentiated sarcomas of children: pathology and clinical behavior--an Intergroup Rhabdomyosarcoma study. Med Pediatr Oncol. 1997;29(3):170-180. 5. Somers GR, Gupta AA, Doria AS, et al. Pediatric undifferentiated sarcoma of the soft tissues: a clinicopathologic study. Pediatr Dev Pathol. 2006;9(2):132-142. 6. Alaggio R, Bisogno G, Rosato A, Ninfo V, Coffin CM. Undifferentiated sarcoma: does it exist? A clinicopathologic study of 7 pediatric cases and review of literature. Human pathology. 2009;40(11):1600-1610. 7. Peters TL, Kumar V, Polikepahad S, et al. BCOR-CCNB3 fusions are frequent in undifferentiated sarcomas of male children. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2015;28(4):575-586. 8. Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval- compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(33):4148-4154. 9. Black JO, Coffin CM, Parham DM, Hawkins DS, Speights RA, Spunt SL. Opportunities for Improvement in Pathology Reporting of Childhood Nonrhabdomyosarcoma Soft Tissue Sarcomas: A Report From Children's Oncology Group (COG) Study ARST0332. American journal of clinical pathology. 2016;146(3):328-338. 10. Spunt SL, Million L, Anderson JR, et al. Risk-based treatment for nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) in patients under 30 years of age: Children’s Oncology Group study ARST0332. Journal of Clinical Oncology. 2014;32(15_suppl):10008-10008. 11. Parham DM, Webber BL, Jenkins JJ, 3rd, Cantor AB, Maurer HM. Nonrhabdomyosarcomatous soft tissue sarcomas of childhood: formulation of a simplified system for grading. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 1995;8(7):705-710. 12. Selvarajah S, Yoshimoto M, Prasad M, et al. Characterization of trisomy 8 in pediatric undifferentiated sarcomas using advanced molecular cytogenetic techniques. Cancer Genet Cytogenet. 2007;174(1):35-41. 13. Pierron G, Tirode F, Lucchesi C, et al. A new subtype of bone sarcoma defined by BCOR- CCNB3 gene fusion. Nat Genet. 2012;44(4):461-466. 14. Italiano A, Sung YS, Zhang L, et al. High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. Genes, chromosomes & cancer. 2012;51(3):207-218. 15. Yamada Y, Kuda M, Kohashi K, et al. Histological and immunohistochemical characteristics of undifferentiated small round cell sarcomas associated with CIC-DUX4 and BCOR-CCNB3 fusion genes. Virchows Arch. 2017. 16. Li WS, Liao IC, Wen MC, Lan HH, Yu SC, Huang HY. BCOR-CCNB3-positive soft tissue sarcoma with round-cell and spindle-cell histology: a series of four cases highlighting the pitfall of mimicking poorly differentiated synovial sarcoma. Histopathology. 2016;69(5):792-801. 17. Hofvander J, Tayebwa J, Nilsson J, et al. Recurrent PRDM10 gene fusions in undifferentiated pleomorphic sarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21(4):864-869. 18. O'Meara E, Stack D, Phelan S, et al. Identification of an MLL4-GPS2 fusion as an oncogenic driver of undifferentiated spindle cell sarcoma in a child. Genes, chromosomes & cancer. 2014;53(12):991-998. 19. Kao YC, Sung YS, Zhang L, et al. Recurrent BCOR Internal Tandem Duplication and YWHAE-NUTM2B Fusions in Soft Tissue Undifferentiated Round Cell Sarcoma of Infancy: Overlapping Genetic Features With Clear Cell Sarcoma of Kidney. Am J Surg Pathol. 2016;40(8):1009-1020. 20. Specht K, Zhang L, Sung YS, et al. Novel BCOR-MAML3 and ZC3H7B-BCOR Gene Fusions in Undifferentiated Small Blue Round Cell Sarcomas. Am J Surg Pathol. 2016;40(4):433- 442. 21. Sugita S, Arai Y, Aoyama T, et al. NUTM2A-CIC fusion small round cell sarcoma: A genetically distinct variant of CIC-rearranged sarcoma. Human pathology. 2017. 22. Fletcher CDM, Unni KK, Mertens F. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone.: IARC Press: Lyon; 2002. 23. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy- number alteration in human cancers. Genome Biol. 2011;12(4):R41. 24. Parsons DW, Roy A, Yang Y, et al. Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. JAMA oncology. 2016. 25. Bainbridge MN, Wang M, Wu Y, et al. Targeted enrichment beyond the consensus coding DNA sequence exome reveals exons with higher variant densities. Genome Biol. 2011;12(7):R68. 26. Reid JG, Carroll A, Veeraraghavan N, et al. Launching genomics into the cloud: deployment of Mercury, a next generation sequence analysis pipeline. BMC bioinformatics. 2014;15:30. 27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481. 28. Peto R, Peto J. Asymptotically Efficient Rank Invariant Test Procedures. Journal of the Royal Statistical Society Series A (General). 1972;135(2):185-207. 29. Liu H, Zilberstein A, Pannier P, et al. Evaluating translocation gene fusions by SNP array data. Cancer informatics. 2012;11:15-27. 30. Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer research. 2008;68(21):8673-8677. 31. Sa JK, Lee IH, Hong SD, Kong DS, Nam DH. Genomic and transcriptomic characterization of skull base chordoma. Oncotarget. 2017;8(1):1321-1328. 32. Heinrich MC, Griffith D, McKinley A, et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012;18(16):4375-4384. 33. Doros LA, Rossi CT, Yang J, et al. DICER1 mutations in childhood cystic nephroma and its relationship to DICER1-renal sarcoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2014;27(9):1267-1280. 34. Matushansky I, Charytonowicz E, Mills J, Siddiqi S, Hricik T, Cordon-Cardo C. MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century. Expert Rev Anticancer Ther. 2009;9(8):1135-1144. 35. Cancer Genome Atlas Research Network. Electronic address edsc, Cancer Genome Atlas Research N. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell. 2017;171(4):950-965 e928. 36. Sandberg AA, Bridge JA. Updates on cytogenetics and molecular genetics of bone and soft tissue tumors: Ewing sarcoma and peripheral primitive neuroectodermal tumors. Cancer Genet Cytogenet. 2000;123(1):1-26. 37. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005;353(21):2243-2253. 38. Liu Z, Yang X, Li Z, et al. CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression. Cell death and differentiation. 2011;18(7):1174-1183. 39. Fujita T, Igarashi J, Okawa ER, et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst. 2008;100(13):940-949. 40. Rosenberg AR, Skapek SX, Hawkins DS. The inconvenience of convenience cohorts: rhabdomyosarcoma and the PAX-FOXO1 biomarker. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2012;21(7):1012-1018. 41. Lynn M, Wang Y, Slater J, et al. High-resolution genome-wide copy-number analyses identify localized copy-number alterations in Ewing sarcoma. Diagnostic molecular pathology : the American journal of surgical pathology, part B. 2013;22(2):76-84. 42. Schofield DE, Fletcher JA, Grier HE, Yunis EJ. Fibrosarcoma in infants and children. Application of new techniques. Am J Surg Pathol. 1994;18(1):14-24. 43. Afify A, Mark HF. Trisomy 8 in embryonal rhabdomyosarcoma detected by fluorescence in situ hybridization. Cancer Genet Cytogenet. 1999;108(2):127-132. 44. Jones L, Wei G, Sevcikova S, et al. Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. The Journal of experimental medicine. 2010;207(12):2581-2594. 45. Tagawa Y, Yasutake T, Ikuta Y, Oka T, Terada R. Chromosome 8 numerical aberrations in stage II invasive ductal carcinoma: correlation with patient outcome and poor prognosis. Med Oncol. 2003;20(2):127-136. 46. Thomas A, Lee JH, Abdullaev Z, et al. Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014;9(4):567-571. 47. Kao YC, Fletcher CDM, Alaggio R, et al. Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma. Am J Surg Pathol. 2018;42(1):28-38. 48. King L, Lopez-Terrada D, Jakacky J, et al. Primary intrathoracic dermatofibrosarcoma protuberans. Am J Surg Pathol. 2012;36(12):1897-1902. 49. Ross JS, Wang K, Chmielecki J, et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. International journal of cancer Journal international du cancer. 2016;138(4):881-890. 50. Sievert AJ, Lang SS, Boucher KL, et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(15):5957-5962. 51. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018;378(8):731-739. 52. Antonescu CR, Owosho AA, Zhang L, et al. Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome: A Clinicopathologic and Molecular Study of 115 Cases. Am J Surg Pathol. 2017;41(7):941-949.